Somatic alterations of fibroblast growth factor receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are currently under investigation in clinical trials for subjects with FGFR gene amplifications, mutations and translocations. Here, we develop cell line models of acquired resistance to FGFR inhibition by exposure of cell lines harboring FGFR3 gene amplification and translocation to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib. We show that the acquisition of resistance is rapid, reversible and characterized by an epithelial to mesenchymal transition and a switch from dependency on FGFR3 to ERBB family members. Acquired resistance was associated with demonstrable changes in gene expression including increased production of ERBB2/3 ligands, which were sufficient to drive resistance in the setting of FGFR3 dependency but not dependency on other FGFR family members. These data support the concept that activation of ERBB family members is sufficient to bypass dependency on FGFR3 and suggest that concurrent inhibition of these two pathways may be desirable when targeting FGFR3-dependent cancers.
INTRODUCTION
The fibroblast growth factors (FGFs) and their cognate receptors (FGFRs) comprise a signaling pathway, which has a critical role in many physiological processes, including cell proliferation, differentiation, migration and survival. FGF signaling is fundamental in embryonic development as well as in regulation of angiogenesis and wound healing in adults. The FGF family consists of 22 ligands, among them, 18 ligands exert their actions through four highly conserved transmembrane tyrosine kinase receptors: FGFR1, FGFR2, FGFR3 and FGFR4. Stimulation of the receptors by ligand binding promotes receptor dimerization and activation of several signaling cascades, including the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. [1] [2] [3] Aberrant activity of FGFRs has been identified in diverse cancer types. FGFRs are activated by gene amplification, point mutation and chromosomal translocation. Amplification of FGFR1 is observed in squamous cell lung cancer, 4, 5 breast cancer 6 and amplification of FGFR2 is found in gastric 7 and breast cancers. 8 Activating point mutations of FGFRs are observed in bladder cancers, 9 endometrial cancers 10 and lung squamous cell carcinoma. 11 Translocations coupled with amplifications and mutations of FGFR3 have been observed in multiple myeloma. 12, 13 More recently, high-throughput sequencing technologies have identified a variety of FGFR gene fusions. FGFR1-TACC1 and FGFR3-TACC3 fusions have been identified in glioblastoma 14 and FGFR3-TACC3 fusions were found in bladder carcinomas and in lung and head and neck squamous cell carcinomas. [15] [16] [17] Preclinical studies have shown that cells harboring FGFR fusions demonstrate dependency on FGFR-mediated signaling, suggesting that cancer patients with FGFR fusions may benefit from targeted FGFR kinase inhibition. 14, 18 Clinical trials to test this hypothesis are underway (www.clinicaltrials.gov).
As preclinical studies have suggested that activated FGFRs are potential targets for cancer therapy, 19 several selective FGFR inhibitors are under investigation in clinical trials 1, 2 with early reports demonstrating clinical efficacy in FGFR1-amplified breast cancer 20 and lung cancer. 21 NVP-BGJ398 (BGJ398) is an example of a selective, potent and orally bioavailable inhibitor of FGFR1/2/3. 22 BGJ398 inhibits the proliferation of various FGFR-dependent cell lines at nanomolar concentrations including lung and breast cancers harboring FGFR1 amplification, gastric cancers harboring FGFR2 amplification and bladder cancers with FGFR3 m utations and/or amplifications. 23 Although FGFR inhibition shows considerable clinical promise, it is expected that patients who initially respond to FGFR inhibitors will become refractory due to the development of acquired resistance. 24 Previous studies have shown that stimulation of some FGFR2-and FGFR3-dependent cell lines with the hepatocyte growth factor decreases sensitivity to FGFR inhibitors and that concurrent inhibition of the epidermal growth factor receptor (EGFR) with pharmacologic inhibitors or RNA interference can potentiate the activity of FGFR inhibitors in some cell lines. 25, 26 In addition, long-term exposure of a FGFR-dependent myeloma cell line to AZD4547 led to the acquisition of a second site (gatekeeper) mutation in FGFR3. 27 Despite these initial observations, the mechanisms governing the acquisition of resistance to FGFR inhibitors remain poorly understood. Therefore, an improved 1 understanding of the molecular mechanisms of acquired resistance to FGFR inhibitors will likely provide valuable insight into how best to use this class of agents.
To study potential mechanisms of acquired resistance to selective FGFR inhibition, we established resistant cells in vitro following long-term exposure to BGJ398. We selected the RT112 bladder cancer cell line which harbors both FGFR3 amplification and a FGFR3-TACC3 fusion as our initial model. Through screening of the activity of 42 membrane receptor tyrosine kinases (RTKs) and mRNA sequencing, we identified that ERBB2 and ERBB3 are activated in the resistant cells in a ligand-dependent fashion. Acquired resistance to FGFR inhibition developed rapidly and was characterized by an epithelial to mesenchymal transition (EMT) along with a switch in dependency from FGFR to ERBB receptor signaling. These results were specific to cell lines with dependency on FGFR3 and were recapitulated using a second FGFR kinase inhibitor, ponatinib.
RESULTS
Phenotypic changes associated with the acquisition of resistance to the pan-FGFR inhibitor BGJ398 in the RT112 cell line RT112 cells that harbor both FGFR3 amplification and the FGFR3-TACC3 fusion, were rendered resistant to BGJ398 by a series of step-wise increases in drug concentration starting at 4 nM (the approximate IC 50 ) until the cells were able to proliferate in 1 μM BGJ398. We selected this cell line for our studies given its dependence on the FGFR3 fusion and anecdotal reports of clinical efficacy of FGFR kinase inhibitors in patients with FGFR3 fusions. These cells were termed BGJ398 RS (BGJ398 Resistant Stepwise). 1 μM was selected as the target final concentration as it is the approximate maximal serum concentration observed in animal and Phase I studies of BGJ398. The cell lines were both insensitive to BGJ398 ( Figure 1A ) and a second, less specific, FGFR kinase inhibitor ponatinib (Supplementary Figure S1 ).
We noted that the BGJ398 RS cells underwent a morphologic change during their acquisition of resistance to BGJ398 from a densely packed adherent layer of small cells to a spindle-like morphology with loss of intercellular adhesion, increased intercellular separation and increased formation of pseudopodia, suggestive of an EMT ( Figure 1B ). EMT has been previously observed in lung cancer in the context of acquired resistance to EGFR inhibitors, 28 prompting us to test whether this transition may also have occurred in our system. We performed real-time PCR analysis of genes previously associated with EMT. We observed that mRNA levels of E-cadherin were downregulated in BGJ398 RS cells and N-cadherin and fibronectin expression were upregulated, consistent with an EMT phenotype ( Figure 1C ) and levels of PLAU, PLAUR, SNAIL and SLUG were slightly but not significantly increased (data not shown). Immunoblots similarly demonstrated a decrease in the protein levels of the epithelial marker E-cadherin and an increase in the mesenchymal markers N-cadherin and fibronectin ( Figure 1D ).
Enhanced cellular migration and invasion are other hallmarks of advanced cancer and metastasis. 29 We therefore assessed migration and invasion using scratch and matrigel invasion assays. BGJ398 RS cells displayed enhanced migration potential in a scratch assay in the presence or absence of BGJ398 treatment as compared to the parental RT112 cell line ( Figure 1E , dimethyl sulfoxide-treated cells), though the cells still demonstrated some sensitivity to BGJ398 in this assay, suggesting that there is ongoing FGFR-dependent signaling in the resistant state ( Figure 1E , BGJ398-treated cells). Similarly, BGJ398 RS demonstrated greater invasion in matrigel coated Boyden chambers as compared with the parental line both in the presence and absence of BGJ398-but as in Figure 1E , resistant cells retained some sensitivity to BGJ398 ( Figure 1F ).
Activation of ERBB2 and ERBB3 in BGJ398 RS cells
We sought to investigate the molecular underpinnings of acquired resistance to BGJ398 in RT112 cells. Given that other studies have implicated the MET gene as a critical mediator of resistance to FGFR inhibitors, 25, 30, 31 we investigated whether levels of total or phospho-MET might be increased in BGJ398 RS. We observed that p-MET was undetectable in the BGJ398-resistant cells and total MET levels slightly decreased (Supplementary Figure S2) ; however, cells resistant to ponatinib demonstrated stability of p-MET and total MET protein (Supplementary Figure S2) .
We next queried the activation status of many cancer-related RTKs using a phospho-RTK array to compare the phosphorylation status of 42 RTKs in RT112 parental cells, RT112 cells treated acutely with BGJ398 and BGJ398 RS cells. We identified two RTKs with increased phosphorylation when comparing the treated and parental lines, ERBB2 and ERBB3 (Figure 2a ). ERBB2 was increased in RT112 cells treated with BGJ398 in the acute setting (1 h) and both ERBB2 and ERBB3 were increased in the final resistant cell populations both in the presence and absence of BGJ398 treatment. Strong phospho-EGFR was maintained in both cell lines and IGF1R was decreased in the resistant line as compared with the parental.
To confirm these results, we performed immunoblots on RT112 cells treated with BGJ398 over a 24-h timecourse. We observed that p-FRS2 and p-FGFR levels decreased with BGJ398 treatment as would be expected ( Figure 2b ). Although levels of phopshoand total EGFR did not change to a substantial degree with BGJ398 treatment, both p-ERBB2 and p-ERBB3 were induced at 12 h following treatment ( Figure 2b ). Similar immunoblots were performed in the BGJ398 RS and ponatinib RS lines; these results are presented in Supplementary Figure S3 . Here, we noted that p-FRS2 levels were below the limits of detection in the resistant lines and that basal levels of p-ERBB2 and p-ERBB3 were higher in the BGJ398 RS and ponatinib RS lines (Supplementary Figure S3 ). p-AKT was also maintained at an increased level of phosphorylation in the resistant lines in the setting of pharmacologic inhibition of FGFRs (Supplementary Figure S3 ).
As these data suggested that ERBB family members may be activated by treatment with FGFR inhibitors and may be having a role in acquired resistance, we assessed the dimerization status of ERBB family members in RT112 cells treated with BGJ398. EGFR, ERBB2 and ERBB3 are known to form homo-or heterodimers when stimulated by their ligands. 32, 33 We performed coimmmunoprecipitation studies and observed an increase in heterodimerization of ERBB2 and ERBB3 in the parental cells after 1 μM BGJ398 stimulation for 24 h as compared with untreated RT112 cells ( Figure 2c) , again suggesting a possible role for ERBB2 and ERBB3 signaling in drug-treated parental cells. The immunoprecipitation assays detected a ERBB2/ERBB3 complex when ERBB2 was immunoprecipitated followed by a ERBB3 immunoblot but this finding was not confirmed in the reverse order.
BGJ398-resistant cell lines are selectively sensitive to tyrosine kinase inhibitors and to shRNA-mediated depletion of ERBB2 or ERBB3 To determine whether increased ERBB2 and ERBB3 signaling is necessary for acquired resistance to BGJ398, we examined whether ERBB inhibition suppressed growth of the resistant cells using a set of ERBB tyrosine kinase inhibitors. RT112 and BGJ398resistant cells were exposed to AZD8931 (EGFR, ERBB2 and ERBB3 inhibitor) or lapatinib (EGFR and ERBB2 inhibitor) alone or in combination with 1 μM BGJ398. The parental RT112 cells were sensitive to BGJ398 but showed little sensitivity to the ERBB family member inhibitors AZD8931 or lapatinib (Figure 3a presents data with AZD8931; Supplementary Figure S4 shows all inhibitor combinations). In contrast, the BGJ398 RS cell line was sensitive to AZD8931 and lapatinib and insensitive to BGJ398 (Figure 3a and Supplementary Figure S4 ). Combined treatment with BGJ398 and AZD8931 resulted in an increased growth inhibition in both the parental and resistant cell lines (Figure 3a ), suggesting a potential ongoing codependency in both cases with a higher degree of FGFR dependency in the parental line and higher ERBB dependency in the resistant line. Similar results were observed for combinations of BGJ398 and lapatinib (Supplementary Figure S4) .
Given that the inhibitor studies suggested a greater degree of FGFR dependence in RT112 and a greater degree of ERBB family member dependence in BGJ398 RS, we next sought to examine effects on signaling of ERBB and ERBB plus FGFR inhibition in the parental and resistant cell lines. The parental and resistant cells were treated with 1 μM AZD8931 alone, 1 μM BGJ398 alone or the two drugs in combination and immunoblots were performed to assess the phosphorylation status of a number of signaling effectors. There was no acute toxicity associated with drug treatments at the assayed timepoint. We observed, as before, that p-FRS2 levels were high in the parental cell line (Figure 3b ). p-FRS2 decreased with BGJ398 treatment but not AZD8931 (Figure 3b ). There was little detectable p-FRS2 in BGJ398 RS as seen in Supplementary Figure S3 . Basal levels of p-ERBB2 and p-ERBB3 were higher in BGJ398 RS as compared with RT112 and sensitive to AZD8931 treatment ( Figure 3b ). Although AZD8931 alone inhibited p-AKT and p-ERK in BGJ398 RS it did not do so in the parental RT112 cells and a combination of BGJ398 and AZD8931 was required to observe a decrease in these signaling effectors, consistent with the concept codependency or rapid dependency switching in the parental line and a switch to a greater degree of ERBB dependency in BGJ398 RS (Figure 3b ).
To address the roles of individual ERBB family members in acquired resistance to BGJ398, we expressed short hairpin RNAs (shRNAs) targeting ERBB2 and ERBB3 using lentiviral vectors in the parental RT112 and BGJ398 RS. We screened a set of shRNAexpressing plasmids for the ability to knockdown ERBB2 or ERBB3 protein (Figure 3c and Supplementary Figure S5 ). We then utilized the shRNA plasmids that drove the greatest depletion of the target and observed that knockdown of endogenous ERBB2 by these shRNAs led to a reduction in proliferation in both cell lines, but with a more robust reduction in BGJ398 RS cells than in parental cells (Figure 3c ), consistent with the inhibitor studies. The effects of ERBB3 depletion were more modest (Supplementary Figure S6A ). ERBB3 was less effectively targeted by the shRNA, perhaps accounting in part for the more modest phenotypes as compared to ERBB2 knockdown (Supplementary Figure S6 ). We next probed shRNA and drug combinations. In the parental cell lines, we observed that knockdown of ERBB2 resulted in a modest decrease in viability, which was potentiated by treatment with BGJ398 (Figure 3d ERBB2 had a greater effect on the viability of BGJ398 RS but there was no additional effect of adding BGJ398 (Figure 3d , left panel). AZD8931 led to death of BGJ398 RS but not parental RT112 cells expressing a shRNA-targeting LacZ (Figure 3d multiple ERBB family members in conferring resistance to BGJ398 (Figure 3d, center panel) . The combination of BGJ398 and AZD8931 led to a substantial decreased viability in RT112 and BGJ398 RS in the presence or absence of shERBB2 (Figure 3d , right panel). A similar trend was seen in the same experiments performed in the context of ERBB3 depletion (Supplementary Figure S6B ).
shRNA-mediated depletion of ERBB2 or ERBB3 leads to decreased migration and invasion in BGJ398-resistant cell lines To assess whether ERBB2 and/or ERBB3 may be having a role in the EMT-like phenotypes observed in Figure 1 , we assessed cellular morphology, migration and invasion in BGJ398 RS cells in the context of shRNA-mediated depletion of either ERBB2 or ERBB3. ERBB2 depletion in BGJ398 RS cells led to a decrease in the spindle-like morphologic changes observed in BGJ398 RS cells expressing a shRNA-targeting LacZ (Figure 4a , × 40 magnification). Depletion of ERBB2 also blunted migration of BGJ398 RS cells in a scratch assay ( Figure 4b ) and invasion in matrigel (Figure 4c ), consistent with partial loss of the EMT-like phenotype. Similar data were observed with ERBB3 depletion, though with more modest results. These data are presented in Supplementary Figure S7 .
Acquired resistance to BGJ398 is reversible and correlated with increased production of ERBB ligands in independent cell line models Other groups have shown that diverse mechanisms of acquired resistance to a single kinase inhibitor in vitro can be observed and may depend on how resistance is generated and may differ among kinase inhibitors with similar target selectivity profiles. 34 To address this issue, we established BGJ398-resistant RT112 cell lines both by stepwise escalation, as described above, and rapid exposure to high concentrations of BGJ398. We also used a second FGFR kinase inhibitor, ponatinib, to generate cell lines using the same protocol to address the generalizability of our results. The resulting BGJ398 RS-(Resistant Stepwise) and BGJ398 RD-(Resistant Direct) resistant cell lines as well as ponatinib RD and ponatinib RS were verified to be resistant to FGFR inhibition by both inhibitors using the Cell-Titer-Glo method (Figure 5a ). Interestingly, we again noted the EMT-like changes in the BGJ398 and ponatinib-resistant RT112 cells derived by rapid inhibitor exposure, similar to what we observed in cells derived by stepwise exposure (Figure 1b ). Given this observation and our previous experiments that showed that ERBB activation occurs within one day of FGFR inhibition in RT112 cells, we reasoned that the acquired resistance may be due to changes in gene transcription and not due to the acquisition of additional somatic mutations, a process that can often take several weeks to arise. Consistent with this hypothesis, sensitivity to BGJ398 or ponatinib could be restored in the resistant cell lines by growth in the absence of drug for two to four weeks (resulting lines termed BGJ398 withdraw and ponatinib withdraw, Figure 5a ) which was accompanied by a morphologic conversion back to the appearance of parental RT112 cells.
As the time-frame for acquisition of resistance to FGFR inhibitors and the reversibility of this phenotype seemed more Figure 4 . shRNA-mediated depletion of ERBB2 leads to decreased migration and invasion in BGJ398-resistant cell lines. BGJ398 RS cells were infected with shRNA-targeting ERBB2 as in Figure 3 or LacZ control. The morphology (a), as well as cell migration (b) and invasion (c) assay were monitored as previously described in Figure 1 . The experiments were performed in triplicate. ***P o0.001.
consistent with transcriptional changes as opposed to acquisition of novel mutations, we performed mRNA sequencing (RNAseq) on parental RT112 as well as the BGJ398 RS or BGJ398 RD cell lines and ponatinib RS and RD. As expected, we noted variable upregulation of EGFR, ERBB2 and ERBB3 in all four of the resistant lines relative to the parental line, suggestive of a common mechanism of resistance (RNAseq data are presented in Supplementary Table 1 ; validation by quantitative PCR in Figure 5b ). We also observed that expression of NRG1, NRG2, NRG4 and BTC, ligands binding to ERBB family receptors, were also generally increased in the resistant cell lines (Figure 5b ). Not all ERBB ligands were upregulated; for example, expression of EGF, HBEGF, AREG and TGFA were unchanged or downregulated in the resistant lines (Figure 5b and Supplementary Table 1 ). To further validate these findings, we performed triplicate Enzyme-linked immunosorbent assay assays on the media from parental RT112 cells and BGJ398 RS. In agreement with the gene expression data, NRG1 protein was undetectable in the parental cell line and averaged 92.7 ± 9.4 pg/ml in BGJ398 RS and EGF was measured at 13.9 ± 0.03 pg/ml in RT112 and 4.5 ± 1.1 pg/ml in BGJ398 RS. NRG2 was undetectable in media from the parental RT112 line and just at the limits of detection in BGJ398 RS averaging 9.8 pg/ml, though the performance of the NRG2 Enzyme-linked immunosorbent assay assay was suboptimal, suggesting that this result should be interpreted cautiously.
Ligand-mediated rescue
It has been previously demonstrated that bypass of dependence on RTKs can be achieved by ligand-mediated activation of alternative RTKs. 25 Given that we observed that BGJ398 drives increased ERBB family activation and that BGJ398 and ponatinib impact the expression of ERBB ligands, we reasoned that ERBB ligands may be important in facilitating the dependency switch. We examined two FGFR3-dependent cell lines, RT112 and RT4, and found that both lines were rendered resistant to BGJ398 treatment if grown in conditioned media from RT112 cells previously treated with BGJ398 ( Figure 6a) . In contrast, two other cells lines with a high degree of sensitivity to FGFR inhibitors, the FGFR1-amplified cell line H1581 and FGFR2 amplified cell line Kato III, could not be rescued by the conditioned media (Figure 6a ). Interestingly, we also obtained similar results using recombinant EGF in which the two FGFR3-dependent lines could be rendered insensitive to BGJ398 treatment but not the FGFR1 or FGFR2dependent line (Supplementary Figure S8) . The effects of conditioned media on sensitivity to BGJ398 in RT112 cells could be blocked in part by a neutralizing antibody targeting NRG1 (Supplementary Figure S9A) .
NRG1 can rescue cell from BGJ398-induced cell death in FGFR3dependent cells
Our RNAseq data suggested that EGF was unlikely to be an important ERBB ligand in the setting of acquired resistance to Figure 5 . Acquired resistance to BGJ398 is reversible and correlated with increased production of ERBB ligands (a) Four resistant cell lines were generated by either stepwise escalation (RS) or high-concentration exposure (RD) to either BGJ398 or ponatinib. Both BGJ398 RS, BGJ398 RD, Ponatinib RS and Ponatinib RD cell lines were verified to be resistant by the Cell-Titer-Glo method. This resistance was reversible as the cells were sensitive to BGJ398 or ponatinib again after drug withdrawal for two to four weeks (BGJ withdraw and ponatinib withdraw). (b) Heatmap representation of the expression of ERBB family members as well as their ligands as determined by by q-PCR. The experiments were repeated twice. FGFR inhibitors in the context of FGFR3 dependency given that it was downregulated with BGJ398 treatment (Figure 5b , Supplementary Table 1 ). NRG1, in contrast, is thought to be one of the principal ligands for stimulation of ERBB2/3 heterodimers 35 and was upregulated in our resistant cell lines (Figure 5b) . As ERBB2 and ERBB3 appeared to be upregulated both at the mRNA and protein level in resistant lines and also demonstrated greater degrees of phosphorylation, we sought to establish whether NRG1 alone could rescue BGJ398-induced death in RT112 and other FGFR-dependent cell lines. Similar to our results from the conditioned media experiments and with EGF stimulation we observed that NRG1 rescued BGJ398-induced death in the FGFR3dependent lines RT112 and RT4 but not the FGFR1-dependent line H1581 or the FGFR2-dependent line Kato III (Figure 6b ). In addition, we probed upregulated ERBB ligand NRG2 and noted that this ligand also demonstrated an observable but more modest degree of protection from BGJ398-induced cell death as compared with NRG1 in the FGFR3-dependent cell lines (Supplementary Figure S9B) . Addition of exogeneous NRG1 or NRG2 was sufficient to drive upregulation of p-ERBB2 and p-ERBB3 in RT112 cells ( Supplementary Figure S9C) .
DISCUSSION
The prevalence of somatic alterations of FGFRs in diverse types of cancer makes FGFRs attractive therapeutic targets. Given that the development of acquired resistance to targeted therapeutic drugs is a major obstacle in cancer medicine, we investigated mechanisms of acquired resistance to both selective and multitargeted FGFR inhibitors. Using unbiased screening to examine the activity of RTKs in the setting of acquired resistance, we found that ERBB2 and ERBB3 were rapidly induced in cells treated with FGFR inhibitors and that resistant cells underwent a dependency switch from predominantly the FGFR to the ERBB signaling pathway, suggesting that signaling through ERBB2/3 can compensate for FGFR inhibition. This switching, in combination with the changes in cellular morphology and the production of ERBB receptor ligands was reversible, indicating substantial plasticity in the interaction among these oncogenic signaling pathways and suggesting a need for dual ERBB/FGFR inhibitors in this setting. Acquired resistance to tyrosine-kinase inhibitors can arise through multiple mechanisms, typically involving second-site mutations in the target gene or by the activation of signaling pathways, which bypass the original target. 30, 31, 36 One commonly implicated bypass signaling pathway is driven by MET, implicated in resistance to FGFR and EGFR inhibitors. 25, 30, 31 MET has been shown to drive EMT transitions and EMT has been observed in the setting of acquired resistance to EGFR directed therapy. 2, [37] [38] [39] Recent data indicate that tumor EMT phenotypes are closely intertwined with the genomic alterations found in tumors and the response of cancers to targeted therapies. There are distinct 'mesenchymal' and 'epithelial' subsets of human bladder cancer cells. The 'mesenchymal' phenotype is associated with FGFR1 expression, whereas 'epithelial' phenotype is associated with FGFR3 expression and sensitivity to BGJ398. 40 We also found that FGFR1 mRNA is upregulated in BGJ398-resistant cells, along with the other mesenchymal markers which may account for the resistance to FGFR inhibitors. In addition, ERBB2 homodimerization and NRG1 secretion have been shown to cause EMT in mammary epithelial cells. [41] [42] [43] Whether EMT is a cause or a result of acquired resistance is unclear and requires further study.
Our findings provide additional mechanistic insight into the ways in which tumors may develop resistance to FGFR inhibitors. Our study provides new details of how cancers may adapt to FGFR inhibition by activating ERBB2/3 in a rapid, reversible and liganddependent fashion. These results are similar to others obtained in the study of BRAF inhibitors in BRAF mutant melanoma and thyroid cancers. 44, 45 Interestingly, these data appear only to apply to cancer cell lines dependent on FGFR3 and not to other FGFRdependent models. This may be due to high basal expression of ERBB family members in these models, which could allow more readily for dependency switching as compared with cell lines in which the ERBB signaling pathway is dormant. This may be similar to the case of hepatocyte growth factor-driven resistance in which cell lines that displayed resistance to BGJ398 in the context of hepatocyte growth factor were noted to express high basal levels of MET. It is likely that additional mechanisms of resistance to FGFR inhibitors will be described in FGFR1 and FGFR2dependent cancers.
Our findings provide preclinical insights into acquired resistance to FGFR inhibitor-based therapy and suggest that dual FGFR/ERBB family inhibition is likely to be more effective than inhibiting either pathway alone in cancers which display either dependency switching or codependency. Given that several small molecule inhibitors and antibodies targeting ERBB family members are being studied in the clinic, it would be reasonable on the basis of our study and the work of others 26 to consider whether dual FGFR and ERBB therapy may be efficacious in FGFR-driven cancers. As several trials of FGFR inhibitors are underway, we will soon learn if FGFR-ERBB dependency switching is observed in patient samples. We hope that these data will motivate additional studies of the response to FGFR inhibitors and mechanisms of resistance and also, together with the work of others, anticipate clinically relevant mechanisms of resistance.
MATERIALS AND METHODS
Cell culture and reagents RT112, RT4, NCI-H1581 and Kato III were obtained from the core collection at Dana-Farber Cancer Institute or Broad Institute and were previously purchased from the American Type Culture Collection (ATCC). RT112, RT4 and Kato III cells were cultured in RPMI 1640, McCoy's 5a and Dulbecco's modified Eagle's medium plus 10% fetal bovine serum. H1581 cells were cultured with ACL-4 medium (Invitrogen, Carlsbad, CA, USA). BGJ398, ponatinib, AZD8931 and lapatinib were purchased from Selleck Chemicals (Houston, TX, USA). All compounds used in the in vitro experiments were prepared as 10 mM stock solutions in dimethyl sulfoxide.
Generation of drug resistant cell lines
Resistant cell lines were established by two different methods: RT112 parental cells were cultured with stepwise escalation of concentrations of BGJ398 or ponatinib from 4 nM to 1 μM (stepwise escalation), with resulting resistant cells named BGJ398 RS or ponatinib RS or initially using a high concentration of BGJ398 or ponatinib (1 μM; high concentration), with resulting resistant cells named BGJ398 RD or ponatinib RD.
Cell proliferation and viability assays
Cell proliferation was measured with the Cell-Titer-Glo reagent (Promega, Madison, WI, USA) following the manufacturer's instructions. Cells were plated into flat-bottomed 96-well plates at a density of 1500 cells per well and were treated the next day with compound or vehicle (dimethyl sulfoxide) for 96 h. Proliferation measurements were made using a luminometer. Data are shown as relative values in which the luminescence at a given drug concentration is compared with that of untreated cells.
Cell migration and transwell invasion assays
For the scratch migration assay, cells were grown to confluence in a monolayer in six-well plates. A linear gap was generated and BGJ398 were added at a final concentration of 1 μM or vehicle into the medium. Microscopic images were acquired at 0 and 24 h. For the transwell migration assay, BD BioCoat invasion chambers (8-μm pore size) coated with Matrigel were used. Cells were serum starved overnight and resuspended in RPMI 1640 containing 0.1% fetal bovine serum. These cells (2.5 × 10 5 cells/chamber) were then added to the top chambers, whereas the bottom chambers contained RPMI 1640 with 10% fetal bovine serum. BGJ398 was added on the top chambers at a final concentration of 1 μM. After 24 h of incubation, the membranes were fixed with methanol and stained with 4,6-diamidino-2-phenylindole. The number of migrated cells was quantified by counting five random distinct fields under a microscope at × 40 magnification. The number of migrated control cells was taken as 100%.
Phospho-RTK array
The activity of a panel of RTKs was screened using an antibody-based array from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instructions. The parental cells or BGJ398 RS cells were treated with 1 μM BGJ398 for 1 h and the cell lysates were incubated with the membrane. Thereafter, a pan anti-phospho-tyrosine antibody was used to detect the phosphorylated tyrosine on activated RTKs.
Immunoblotting analysis
Following treatment, cells were lysed in RIPA. Equal amounts of protein were analyzed by SDS-polyacrylamide gel electrophoresis. Primary antibodies used were as follows: Phospho-FGF Receptor (Tyr653/654, 55H2, #3476S), FGF Receptor 3 (C51F2, #4574S), Phospho-FRS2-α (Tyr436, #3861S), Phospho-ERBB2 (Y1221/1222, #2243S), Phospho-ERBB3 (Y1289, #4791S), Phospho-EGFR (Y1068, 1H12, #2236S), AKT (#9272S), Phospho-AKT (Ser473, D9E, #4060S), Phospho-ERK1/2(T202/Y204, #4370S), ERK1/2 (137F5, #4695S) were from Cell Signaling Technologies (Beverly, MA, USA). FRS2 (H-91, sc-8318) was purchased from Santa Cruz (Santa Cruz, CA, USA). ERBB2 (e2-4001) was from NeoMarkers (Fremont, CA, USA), ERBB3 (#MA5-12675) was from Thermo Scientific (Waltham, MA, USA). EGFR (#A300-388A) was from Bethyl Antibodies (Montgomery, TX, USA).
ShRNA constructs and lentiviral infection
ERBB2 and ERBB3 shRNA were obtained from TRC (RNAi Consortium at the Broad Institute, Cambridge, MA, USA). 46 The target sequence of the shRNA constructs are: ERBB2: TGTCAGTATCCAGGCTTTGTA, ERBB3: GCCTACCA GTTGGAACACTTA. A vector containing LacZ sequence was used as control. Lentiviral infections were performed according to the online TRC protocol (http://www.broadinstitute.org/rnai/public/resources/protocols) with 293T cells transfected with the suggested 3-vector combination. Virus was collected and used to infect the RT112 or BGJ398 RS cell lines for 6 h in the presence of 8 μg/ml polybrene. Stable cell lines were generated using puromycin selection at a concentration of 2 μg/ml. Knockdown was confirmed by immunoblot.
Immunoprecipitation
For the detection of ERBB2/ERBB3 dimerization, whole-cell lysates (1 mg) in NP40 lysis buffer was incubated with agarose A/G plus preconjugated with the ERBB2 or ERBB3 antibody. Immunoprecipitates were washed in lysis buffer, boiled in sample buffer and subjected to SDS-polyacrylamide gel electrophoresis followed by immunoblotting using an anti-ERBB2 or anti-ERBB3 or anti-EGFR to detect specific dimerization of ERBB family members.
RNA sequencing (RNAseq) analysis
Total RNA was prepared using the Qiagen RNeasy kit (Venlo, Limburg, Netherlands). Libraries were prepared using the NEBNext library Prep Kit (New England Biolabs, Ipswich, MA, USA) according to the manufacturer's instructions. Library quality was assessed using a Bioanalyzer (Agilent, Santa Clara, CA, USA) and then were sequenced on the Illumina Hiseq 2000 with a goal of 30 million reads per sample. Raw FASTQ files were aligned using PRADA and FPKM values obtained using Cufflinks for gene expression analysis.
Real-time PCR
Total RNA was reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-rad, Hercules, CA, USA). Quantitative real-time PCR (q-PCR) analysis was performed using a MyiQ real-time PCR Detection System (Bio-rad) and the SYBR Green q-PCR kit (Bio-Rad). Glyceraldehyde-3phosphate dehydrogenase mRNA levels were used as internal controls in the qRT-PCR analysis.
Enzyme-linked immunosorbent assay
The supernatant was collected from parental and BGJ398 RS cell line 48 h after media change, and stored at − 80°C until measurement. The ERBB family liands NRG1, NRG2, NRG4 and EGF were measured using the Enzymelinked immunosorbent assay kit (Abnova for NRG1, Cloud-clone for NRG2 and NRG4, R&D for EGF) according to the manufacturer's instructions.
Statistical analysis
All data are expressed with mean ± standard derivation (s.d.), IC 50 values were obtained using GraphPad Prism software (La Jolla, CA, USA). Statistical significance was calculated by Student's t test, considering Po0.05 as statistically significant.
